Wolverine Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$250K Hold
1,322
﹤0.01% 1059
2025
Q4
$225K Buy
1,322
+1,237
+1,455% +$190K ﹤0.01% 1090
2025
Q3
$11.2K Buy
+85
New +$10.2K ﹤0.01% 1354
2024
Q3
Sell
-15,804
Closed -$1.73M 1715
2024
Q2
$1.69M Buy
15,804
+4,900
+45% +$539K 0.02% 551
2024
Q1
$1.31M Buy
10,904
+5,100
+88% +$625K 0.02% 586
2023
Q4
$714K Sell
5,804
-3,500
-38% -$437K 0.01% 798
2023
Q3
$1.2M Buy
9,304
+300
+3% +$40K 0.01% 675
2023
Q2
$1.12M Buy
+9,004
New +$1.21M 0.01% 657
2021
Q3
Sell
-1,416
Closed -$251K 2169
2021
Q2
$251K Buy
1,416
+348
+33% +$60.3K ﹤0.01% 1159
2021
Q1
$175K Sell
1,068
-468
-30% -$77K ﹤0.01% 1275
2020
Q4
$253K Buy
+1,536
New +$229K ﹤0.01% 1036
2020
Q2
Sell
-3,902
Closed -$389K 1660
2020
Q1
$389K Buy
+3,902
New +$505K 0.01% 743

Other funds holding JAZZ

Wolverine Asset Management's JAZZ Position: Q1 2026 in Review

Wolverine Asset Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 1,322 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Wolverine Asset Management first reported a position in JAZZ in Q1 2020 and has held it in 12 quarters since. The position peaked at $1.69M in Q2 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Wolverine Asset Management held 1,322 shares of Jazz Pharmaceuticals worth $250K as of Q1 2026.
  • Wolverine Asset Management left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1059 holding.
  • Wolverine Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
  • Wolverine Asset Management's Jazz Pharmaceuticals position peaked at $1.69M in Q2 2024.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.